×

Akers Bio Signs Distribution Agreement With ADS for U.S. Govt.

THOROFARE, N.J., April 2, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has signed an exclusive Master Distributor Agreement with ADS Inc. ("ADS") for the marketing and supply of Akers' rapid diagnostic assays to U.S. Government agencies and departments (the "Agreement").

ADS is the premier equipment procurement and support solutions specialist to the military, law enforcement, first responders and the defense industries in the United States.

The Agreement, which has an initial term of eighteen months, spans the entirety of Akers' product catalog but will focus initially on marketing the Company's rapid test for Heparin-Induced Thrombocytopenia (an allergic condition associated with the commonly used blood-thinner Heparin, generally used in various surgical procedures); the Company's rapid, light-weight test for determining blood type compatibility in remote locations; and the Company's range of rapid tests for infectious diseases including Malaria and Dengue Fever.

"Akers and ADS have identified a number of areas in which U.S. Government departments such as the Department of Defense could benefit significantly from the introduction of the Company's rapid diagnostic assays," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of the Board.

"These include the introduction of the Company's PIFA Heparin/PF4 rapid assays to military hospitals in order to reduce the costs and risks associated with the use of Heparin as a blood-thinning agent; our rapid blood-typing card for use in blood transfusions under battlefield conditions; and tests for infectious diseases such as Malaria and Dengue Fever out in the field or in remote locations where speed and ease of diagnosis are of paramount importance," continued Dr. Akers.

"ADS is the preeminent distributor to this important target market so we are delighted to partner with them through this agreement to reach these large potential customers," added Dr. Akers.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

ABOUT ADS INC.

ADS Inc. is a leading solutions provider that proudly serves all branches of the U.S. Military, federal, state and local government organization, law enforcement, first responders, foreign governments and the defense industry. The company is focused on solving customers' challenges through the largest product and service selection, the broadest array of procurement and contract options, world-class support and logistics solutions and legendary customer service. ADS is a single source that actively seeks out customers' equipment and logistics challenges to deliver innovative and cost-effective solutions that help them complete their mission and maintain readiness. ADS equipment and support solutions include C4ISR, Combat Support, Medical, Operational Clothing and Individual Equipment (OCIE), Weapons and Optics as well as Special Missions, including CWMD, CBRNe EOD, First Responders and Maritime Operations.

Additional information can be found at www.adsinc.com.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information: Akers Biosciences, Inc. Raymond F. Akers, Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220 0500 Taglich Brothers, Inc. (US Investor Relations) Chris Schreiber Tel. +1 917 445 6207 Vigo Communications (UK Investor Relations) Ben Simons / Fiona Henson Tel. +44 (0)20 7016 9570 akers@vigocomms.com

Source:Akers Biosciences, Inc.